Kringle Pharma (4884) · RiskRestated
Uncertainty surrounding future revenue projections
First written in FY2020. 1 of 2 entries say "Restated". Latest entry: FY2022.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Uncertainty in License Milestone RevenueA theme 19 companies write about · 19 as a headwind · 1 as a tailwind
The whole theme swung hardest in 2019: 2 of 6 companies on the "Worse" side.
13 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 19 companies compared. The sentences above are computed from all 19.Full recordFilings, disclosures and news, newest first
- FY2022RestatedAnnual report
「類似製品の選定が困難な場合、及び類似製品からの価格の推定が困難な場合があり、将来の収益の計画が大きく変更する可能性があります。」
希少疾患薬の類似製品・価格推定の困難さや、開発進捗に伴う収益時期・金額の変動リスクを再掲している。 - FY2020First statedAnnual report
「However, because the company is developing treatments for intractable diseases, it may be difficult to identify comparable products or estimate prices based on comparable products, and future revenue plans may change significantly.」
The company cites difficulty estimating comparable products and prices, as well as changes in the timing and amount of upfront fees and milestones depending on development progress.